Медикаментозная органопротекция при операциях аортокоронарного шунтирования в условиях искусственного кровообращения
Еременко А.А., Зюляева Т.П., Егоров В.М., Фоминых М.А. Медикаментозная органопротекция при операциях аортокоронарного шунтирования в условиях искусственного кровообращения. Consilium Medicum. 2008; 10 (8): 115–117.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Короткина Р.Н., Коростелев А.Н., Ситников А.В., и др. Метаболические эффекты Мексидола при кардиохирургических операциях с искусственным кровообращением. Анестезиология и реаниматология. 2005; 3: 21–23.
2. Шевченко О.П., Хубутия М.Ш., Чернова А.В. и др. Молекулярные и клеточные механизмы развития осложнений после искусственного кровообращения. Трансплантология и искусственные органы. – 1996; 3: 49–55.
3. Ascione R, Talpahewa S, Rajakaruna C, Reeves B.C., Lovell AT, Cohen A, Angelini G.D. Splanchnic Organ Injury During Coronary Surgery With or Without Cardiopulmonary Bypass: A Randomized, Controlled Trial. Ann Thorac Surg 2006; 81: 97–103.
4. Bone R.S. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and not know about cytokine regulation. Crit Care Med 1996; 24 (1): 163–72.
5. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996; 27(suppl. 1):S1–S5
6. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg, Jul 2003; 76: 117 – 123.
7. Hess PJ. Systemic Inflammatory Response to Coronary Artery Bypass Graft Surgery. Am J Health-Syst Pharm. 2005; 62(18): 6–9.
8. Kumle B, Boldt J, Suttner SW, Piper SN, Lehmann A, Blome M. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg, 2003 May;75(5):1558–64.
9. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002, Jul; 97(1): 215–52.
10. Lefor AT, Vuocolo P, Parker FB Jr, Sillin LF. Pancreatic complications following cardiopulmonary bypass: factors influencing mortality. Arch Surg 1992;127:1225–30.
11. O’Dwyer C, Woodson LC, Conroy BP, et al. Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 1997; 63: 728–35.
12. Ohri SK, Bjarnason I, Pathi V, Somasundaram S, Bowles CT, Keogh BE, Khaghani A, Menzies I, Yacoub MH, Taylor KM. Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann Thorac Surg, 1993 May; 55(5):1080–6.
13. Riddington DW, Venkatesh B, Boivin CM et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996; 275: 1007–12.
14. Schroter J, Wandel C, Bohrer H, Schmidt H, Bottiger BW, Martin E. Lidocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995; 50: 850–4.
15. Wang MJ, Chao A, Huang CH et al. Hyperbilirubinemia after cardiac operation. Incidence, risk factors, and clinical significance. J Thorac Cardiovasc Surg 1994; 108: 429 –36.
2. Шевченко О.П., Хубутия М.Ш., Чернова А.В. и др. Молекулярные и клеточные механизмы развития осложнений после искусственного кровообращения. Трансплантология и искусственные органы. – 1996; 3: 49–55.
3. Ascione R, Talpahewa S, Rajakaruna C, Reeves B.C., Lovell AT, Cohen A, Angelini G.D. Splanchnic Organ Injury During Coronary Surgery With or Without Cardiopulmonary Bypass: A Randomized, Controlled Trial. Ann Thorac Surg 2006; 81: 97–103.
4. Bone R.S. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and not know about cytokine regulation. Crit Care Med 1996; 24 (1): 163–72.
5. Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol 1996; 27(suppl. 1):S1–S5
6. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg, Jul 2003; 76: 117 – 123.
7. Hess PJ. Systemic Inflammatory Response to Coronary Artery Bypass Graft Surgery. Am J Health-Syst Pharm. 2005; 62(18): 6–9.
8. Kumle B, Boldt J, Suttner SW, Piper SN, Lehmann A, Blome M. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg, 2003 May;75(5):1558–64.
9. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002, Jul; 97(1): 215–52.
10. Lefor AT, Vuocolo P, Parker FB Jr, Sillin LF. Pancreatic complications following cardiopulmonary bypass: factors influencing mortality. Arch Surg 1992;127:1225–30.
11. O’Dwyer C, Woodson LC, Conroy BP, et al. Regional perfusion abnormalities with phenylephrine during normothermic bypass. Ann Thorac Surg 1997; 63: 728–35.
12. Ohri SK, Bjarnason I, Pathi V, Somasundaram S, Bowles CT, Keogh BE, Khaghani A, Menzies I, Yacoub MH, Taylor KM. Cardiopulmonary bypass impairs small intestinal transport and increases gut permeability. Ann Thorac Surg, 1993 May; 55(5):1080–6.
13. Riddington DW, Venkatesh B, Boivin CM et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996; 275: 1007–12.
14. Schroter J, Wandel C, Bohrer H, Schmidt H, Bottiger BW, Martin E. Lidocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995; 50: 850–4.
15. Wang MJ, Chao A, Huang CH et al. Hyperbilirubinemia after cardiac operation. Incidence, risk factors, and clinical significance. J Thorac Cardiovasc Surg 1994; 108: 429 –36.
Авторы
А.А. Еременко, Т.П.Зюляева, В.М.Егоров, М.А.Фоминых
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.